Episode Details

In his weekly clinical update, Dr. Griffin reviews most recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus in the US before discussing vaccine effectiveness in children and adolescents, how the pandemic impacted the socioemotional development of infants and toddlers, continues to dispel the myth of viral rebound, how to pay for Paxlovid, reviews quarantine guidelines, when to use steroids and the benefits of convalescent plasma, examines the role of immune aberrations in long COVID and how vaccination may protect against developing long COVID.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Influenza/flu surveillance  (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend(CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC)
• Remember when COVID was bad? (Wired)
• Children and adolescents hospitalized with SARI (Pediatrics)
• COVID-19 vaccines are effective for adolescents (Pediatrics)
• Vaccine effectiveness against long COVID in children (Pediatrics)
• Infant and toddler socioemotional development in the pandemic (JAMA)
• Quarantine/isolation guidelines (CDC)
• Should I take Paxlovid? (NY Times)
• What is this about Paxlovid rebound? (CDC)
• Rebound is NOT the early inflammatory phase (ESMED)
• How